Introduction and Objective: MASLD affects more than one-third of the adult population and is strongly associated with obesity and T2D. Early detection of hepatic steatosis and fibrosis is essential to prevent progression to advanced liver disease, yet access to 2-step noninvasive liver screening remains limited in primary care settings. FibroScan implementation provides a rapid assessment of liver fat and stiffness but typically requires trained operators. This study evaluated whether non-ultrasonography technicians could provide reliable FibroScan measurements in primary care. Methods: Adults ≥18 years were recruited from a university metabolic research center and the surrounding community. Five trained operators performed FibroScan measurements using the EchoSens FibroScan device. Participants underwent assessment of liver stiffness (kPa) and controlled attenuation parameter (CAP). The operators were allowed ≤ 10 minutes to complete the scan. All participants had at least two scanners per screening episode. Intraclass correlation coefficients (ICC) were used to evaluate intra- and inter-rater reliability. Inter-rater reliability was assessed with an additional 30 paired scans obtained by two operators. Results: A total of 100 participants underwent FibroScan evaluation. Inter-rater reliability demonstrated good agreement for CAP (ICC 0.81, 95% CI 0.66-0.90) and excellent agreement for liver stiffness (ICC 0.94, 95% CI 0.89-0.97). Intra-rater reliability demonstrated excellent reproducibility for CAP (ICC ≈0.93) and liver stiffness (ICC ≈0.96). All reliability measures were statistically significant (p0.05). Conclusion: FibroScan measurements performed by trained non-ultrasound personnel demonstrated high inter- and intra-rater reliability in a community-based screening program. These findings suggest that FibroScan can be feasibly implemented in primary care settings to support early detection of metabolic liver disease and improve access to liver health screening. Disclosure I.H. Maldonado: None. T.D. Dela Rueda: None. Y. Sadati: None. G.D. Brannan: None. J. Shubrook: Advisory Panel; Current; Abbott Diabetes. Other - Doc Care Deputy EditorConsensus panel-liver health, screening early stage T1d, Technology in primary care; Current; American Diabetes Association. Advisory Panel; Current; Bayer AG, Boehringer Ingelheim International GmbH. Consultant; Ended; Corcept Therapeutics. Advisory Panel; Ended; Idorsia Pharmaceuticals Ltd. Advisory Panel; Current; Insulet Corporation. Advisory Panel; Ended; Madrigal Pharmaceuticals, Inc. Consultant; Current; Novo Nordisk, Sanofi.
MALDONADO et al. (Fri,) studied this question.